AVITA Medical Inc Cash Flow Conversion Efficiency
AVITA Medical Inc cash flow conversion efficiency. Based on the latest financial reports, AVITA Medical Inc (51KB) has a cash flow conversion efficiency ratio of 2.255x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.31 Million ≈ $-12.05 Million USD) by net assets (€-4.57 Million ≈ $-5.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AVITA Medical Inc (2019–2024)
Cash flow conversion efficiency of AVITA Medical Inc from 2019 to 2024. This chart illustrates how AVITA Medical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for AVITA Medical Inc for real-time trading data and today's change.
AVITA Medical Inc Cash Flow Conversion Ratio Explained
AVITA Medical Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AVITA Medical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AVITA Medical Inc ranked by their cash flow conversion efficiency. Also see market cap of AVITA Medical Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bhageria Industries Limited
NSE:BHAGERIA
|
0.048x |
|
Imarketkorea
KO:122900
|
0.029x |
|
Xi S And D Inc
KO:317400
|
0.017x |
|
Energy Services Of America Corp
NASDAQ:ESOA
|
-0.034x |
|
Sinar Mas Multiartha Tbk
JK:SMMA
|
0.075x |
|
Robot Consulting Co., Ltd. ADS
NASDAQ:LAWR
|
N/A |
|
Bonei Hatichon Civil Engineering and Infrastructures Ltd
TA:BOTI
|
-0.557x |
|
New World Resources Ltd
AU:NWC
|
-0.015x |
Annual Cash Flow Conversion Efficiency for AVITA Medical Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of AVITA Medical Inc from 2019 to 2024. Review AVITA Medical Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | €49.06 Million ≈ $57.35 Million |
€-38.01 Million ≈ $-44.44 Million |
-0.775x | -243.95% |
| 2023-06-30 | €84.74 Million ≈ $99.07 Million |
€-19.09 Million ≈ $-22.32 Million |
-0.225x | -0.59% |
| 2021-06-30 | €115.66 Million ≈ $135.21 Million |
€-25.90 Million ≈ $-30.28 Million |
-0.224x | +28.72% |
| 2020-06-30 | €72.40 Million ≈ $84.64 Million |
€-22.75 Million ≈ $-26.59 Million |
-0.314x | +65.95% |
| 2019-06-30 | €20.86 Million ≈ $24.39 Million |
€-19.25 Million ≈ $-22.50 Million |
-0.923x | -- |
About AVITA Medical Inc
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitili… Read more